Arizona School District Reaches Settlement with Altria for $3.2 Million.

Aug.24.2023
Arizona School District Reaches Settlement with Altria for $3.2 Million.
Tucson Unified School District (TUSD) reaches $3.2 million settlement with Altria as part of a collective lawsuit.

On August 24, the Tucson Unified School District (TUSD) in Arizona announced a settlement with Altria, in which they will receive a settlement amount of $3.2 million. Previously, the district had reached a settlement of around $10 million with Juul, both being part of the same class action lawsuit.

 

Dr. Ravi Shah, President of TUSD, stated:

 

Our staff has devoted a substantial amount of time conducting research, gathering evidence, and analyzing various aspects, all of which demonstrate the impact of Juul and Altria, as well as their influence on our school district.

 

The school district will begin receiving this sum of money starting at the end of this year and will continue to receive the remaining settlement funds in the coming years. The district's attorneys will receive 25% of the compensation amount. After deducting this fee, the school district will be left with approximately $10.3 million from these two settlements.

 

Ravi hopes that every cent of this money will be used to aid in the prevention and treatment of addiction issues among our students, as well as to meet their mental health needs. He stated that the school district already has plans in place to assist students, but the additional funding will further support their efforts.

 

Previously, Altria Group announced that it will pay $235 million to settle at least 6,000 lawsuits.

 

This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Cambodia Enforces Full Ban on E-Cigarettes and Shisha to Protect Youth
Cambodia Enforces Full Ban on E-Cigarettes and Shisha to Protect Youth
Cambodian Prime Minister Hun Manet signs order to strengthen enforcement of e-cigarette and shisha bans, citing health risks and youth usage.
Oct.23 by 2FIRSTS.ai
KT&G Unveils lil hybrid 3.0 Misty Rose Limited Edition, Limited to 20,000 Devices
KT&G Unveils lil hybrid 3.0 Misty Rose Limited Edition, Limited to 20,000 Devices
KT&G has launched the limited-edition “lil hybrid 3.0 Misty Rose Edition” heated tobacco device in South Korea, betting on year-end consumer demand with a gradient rose-colored design. The release is capped at 20,000 units and is available through both online and offline channels, with an official retail price of 78,000 won (approximately USD 53).
Nov.20 by 2FIRSTS.ai
Smoore’s Q3 Revenue Hits Record High, Reflecting Structural Growth in Global HNB and E-Vapor Markets
Smoore’s Q3 Revenue Hits Record High, Reflecting Structural Growth in Global HNB and E-Vapor Markets
Smoore posted record-high Q3 2025 revenue, driven by growth in both HNB and e-vapor segments, reflecting ongoing expansion of the global next-generation tobacco industry amid compliance and structural upgrades.
Oct.12
Product | Magnetic-attach design + mini display: FASTA’s new product goes on sale in the U.S., priced around $16
Product | Magnetic-attach design + mini display: FASTA’s new product goes on sale in the U.S., priced around $16
FASTA’s 40K Kit hits U.S. retailers: magnetic prefilled pods + reusable battery, mini display, two power levels; rated 20 mL/40,000 puffs/50 mg; some listings at $15.99.
Oct.15 by 2FIRSTS.ai
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International announced that the U.S. FDA has accepted the Abbreviated New Drug Application (ANDA) for its Breo® Ellipta® 100/25 generic drug, submitted by its wholly-owned subsidiary, Transpire Bio. Transpire Bio stated that if approved, it is expected to receive 180 days of market exclusivity. In the United States, Breo® Ellipta® is already approved for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).
Sep.25 by 2FIRSTS.ai
EU Cardiovascular Health Plan Consultation Highlights Tobacco Debate — 2Firsts Analysis Reveals Divide Between “Cessation” and “Harm Reduction” Approaches
EU Cardiovascular Health Plan Consultation Highlights Tobacco Debate — 2Firsts Analysis Reveals Divide Between “Cessation” and “Harm Reduction” Approaches
As the EU finalizes its Cardiovascular Health Plan, public feedback reveals a sharp divide over nicotine policy.A 2Firsts analysis of 677 submissions found that nearly one in four mentioned tobacco — highlighting tension between strict control and harm reduction approaches.
Oct.07